Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03990363 · ClinicalTrials.gov registry record · Phase 2
A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 861
- Enrollment target
NCT03990363: Completed Phase 2 study, sponsored by AstraZeneca.
NCT03990363 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 861 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (547% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03990363, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 861 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to establish the dose of verinurad combined with allopurinol 300 mg once daily that will elicit the desired response; ie, reduction in urinary albumin to creatinine ratio (UACR) at 6 months.
Primary Outcome
Analyses of change from baseline in uACR at 6 months (Visit 8) focused on: * High dose vs Placebo * High dose and Inter. dose combined vs Allopurinol alone * Inter. dose vs Placebo * Low dose vs Placebo * High dose vs Allopurinol * Inter. dose vs Allopurinol * Low dose vs Allopurinol * Allopurinol vs Placebo For High dose and Inter. dose combined the 2 categories merged forming 1 new temporary category.
Interventions
- DRUG Allopurinol
- DRUG Verinurad
- DRUG Placebo for Verinurad
- DRUG Placebo for Allopurinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 861 participants |
| Start Date | 2019-07-23 |
| Est. Completion | 2021-11-22 |
| Phase | Phase 2 |
What the finished NCT03990363 record still lists
NCT03990363 is an interventional study that assigns participants to a tested intervention. The registered 861 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (547% higher).
The record links to 0 conditions, and to 4 interventions - of which Allopurinol is the first listed.
NCT03990363 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03990363 about?
NCT03990363 is a clinical study titled "A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia". The purpose of this clinical research study is to establish the dose of verinurad combined with allopurinol 300 mg once daily that will elicit the desired response; ie, reduction in urinary albumin to creatinine ratio (UACR) at 6 months.
What is the current status of trial NCT03990363?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 861 participants. The study started on 2019-07-23. Estimated completion is 2021-11-22.
What interventions are being tested in trial NCT03990363?
The interventions under investigation include: Allopurinol (DRUG), Verinurad (DRUG), Placebo for Verinurad (DRUG), Placebo for Allopurinol (DRUG).
Who is sponsoring clinical trial NCT03990363?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03990363's enrollment target sits among peer trials
861 33rd of 2000 higher than 1,968 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05914116 · 862 participants · Phase 1
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- NCT04541381 · 860 participants · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
- NCT05211895 · 860 participants · Phase 3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- NCT06161025 · 860 participants · Phase 2
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI